No Data
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Is it the most 'rolled up' in history? The tenth batch of national procurement pharmaceutical catalog is officially announced, with up to 31 companies competing for a single variety.
①This afternoon, the National Pharmaceutical Centralized Procurement Office officially announced the tenth batch of national procurement pharmaceutical catalog, with a total of 263 specifications and 62 varieties; ②Many industry insiders believe that the tenth batch of national procurement will be the largest and most competitive national procurement in history.
hansoh pharma (03692.HK): The National Medical Products Administration has approved the B7-H3 targeted antibody-drug conjugate HS-20093 for breakthrough therapy.
格隆汇November 1st | Hansoh Pharma (03692.HK) announced that on November 1, 2024, the group's self-developed B7-H3 targeted antibody-drug conjugate ("ADC") injection HS-20093 was approved by the National Medical Products Administration (NMPA) of China as a breakthrough therapeutic drug, intended for the treatment indication of extensive-stage small cell lung cancer (ES-SCLC) progressing after standard first-line treatment (including platinum doublet chemotherapy combined with immunotherapy). HS-20093 is a novel B7-H3 targeted ADC, consisting of a fully human anti-B7-H3 monoclonal antibody and a topoisomerase inhibitor.
hansoh pharma (03692.HK) HS-20093 included in breakthrough therapeutic drugs.
Hansoh Pharma (03692.HK) announced that on November 1st, the group's self-developed B7-H3 targeted antibody-drug conjugate injection HS-20093 has been approved by the National Drug Administration for inclusion as a breakthrough therapeutic drug, with the indication planned for extensive-stage small cell lung cancer progressing after standard first-line treatment.
The Hong Kong stock sector generally fell with trading volume increasing to 160 billion Hong Kong dollars. Institutions believe that the Hang Seng Index at 19,500 points is worth absorbing.
Produced jointly by Zhongtai International and CaiLian News.
Zheshang Securities: Continuous realization of technological innovation upgrades driving the continuous improvement of performance expectations for innovative drugs and industry chains.
As the innovative drugs industry chain enters the commercialization realization period driven purely by incremental growth, the scarcity of incremental prosperity in the pharmaceutical sector continues to rise, international competitiveness continues to improve, and there is still room for upward valuation.
No Data
No Data